Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Current Assets (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Current Assets for 6 consecutive years, with $101.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 58.61% to $101.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $101.9 million, a 58.61% decrease, with the full-year FY2025 number at $101.9 million, down 58.61% from a year prior.
  • Current Assets was $101.9 million for Q4 2025 at Lexicon Pharmaceuticals, down from $122.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $364.6 million in Q1 2024 to a low of $101.9 million in Q4 2025.
  • A 3-year average of $215.7 million and a median of $234.6 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 232.87% in 2024, then tumbled 58.61% in 2025.
  • Lexicon Pharmaceuticals' Current Assets stood at $176.5 million in 2023, then surged by 39.45% to $246.2 million in 2024, then plummeted by 58.61% to $101.9 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Current Assets are $101.9 million (Q4 2025), $122.5 million (Q3 2025), and $145.1 million (Q2 2025).